冠状动脉无复流现象的当前认识
《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]
- 期数:
- 2016年第2期
- 页码:
- 226-230
- 栏目:
- 综述
- 出版日期:
- 2015-11-25
文章信息/Info
- Title:
- Current understanding of no-reflow phenomenon
- Author(s):
- LI Shao-hui; WANG Hai-chang; ZHANG Ying-mei
- (Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
- 关键词:
- 无复流; 经皮冠状动脉介入治疗; 心肌梗死; 再灌注
- 分类号:
- R541.4
- DOI:
- -
- 文献标识码:
- A
- 摘要:
- 经皮冠状动脉介入治疗（PCI）是急性ST段抬高性心肌梗死患者的首选治疗策略。虽然PCI后冠脉血流恢复，但仍经常观察到无复流现象，并且与较差的临床预后有关。导致该现象的病因机制复杂且相互关联，对这些机制的进一步认识有助于制定个性化的预防和治疗策略。可以使用冠脉造影、心肌对比超声及心脏磁共振等技术诊断无复流。许多药物可能改善实验室和临床无复流，但一些药物尚未明确地改善临床结果。
- Abstract:
- Primary percutaneous coronary intervention (PCI) is the preferred treatment for ST segment elevation myocardial infarction. Although there is restoration of coronary flow after PCI, no-reflow phenomenon is frequently observed and may lead to poor prognosis. The pathogenic mechanisms that cause this phenomenon are complex and interrelated. A better understanding of these mechanisms could promote the development of individualized prevention and treatment strategies. Diagnosis of ‘no-reflow’ can be made using angiography, myocardial contrast echocardiography or cardiovascular magnetic resonance. A number of drugs may improve no-reflow experimentally and clinically, but some have not yet been associated with conclusive improvements in clinical outcome.
参考文献/References
[1]Celik T,Iyisoy A,Yuksel UC,et al.The impact of admission C-reactive protein levels on the development of slow or no reflow after primary PCI in patients with acute myocardial infarction: the role of inflammation[J].Int J Cardiol, 2009,136(1):86-88.
[2]Ndrepepa G,Tiroch K,Fusaro M,et al.5-year prognostic value of slow or no reflow after percutaneous coronary intervention in patients with acute myocardial infarction[J].J Am Coll Cardiol,2010,55(21):2383-2389.
[3]Gu YL,Kampinga MA,Wieringa WG,et al.Intra-coronary versus intravenous administration of abciximab in patients with ST segment elevation myocardial infarction undergoing primary percu-taneous coronary intervention with thrombus aspiration: the Comparison of Intracoronary versus Intravenous Abciximab Administration during Emergency Reperfusion of ST-Segment ElevationMyocardial Infarction(CICERO)trial[J].Circulation,2010,122(25):2709-2717.
[4]White SK,Hausenloy DJ,Moon JC.Imaging the myocardial microcirculation post-myocardial infarction[J].Curr Heart Fail Rep,2012,9(4):282-292.
[5]Rezkalla SH,Kloner RA.Coronary slow or no reflow:from the experimental laboratory to the cardiac catheterization laboratory[J].Catheter Cardiovasc Interv,2008,72(7):950-957.
[6]Soylu K,Yuksel S,Gulel O,et al.The relationship of coronary flow to neutrophil/lymphocyte ratio in patients undergoing primary percu-taneous coronary intervention[J].J Thorac Dis,2013,5(3):258-264.
[7]Jiao Q,Ke Q,Li W,et al.Inflammatory factor increases cyclooxygenase expression on the development of no-reflow[J].Clin Exp Pharmacol Physiol,2015,42(2):162-170.
[8]Duygu H,Turkoglu C,Kirilmaz B,et al.Effect of mean platelet volume on postintervention coronary blood ?ow in patients with chronic stable angina pectoris[J].J Invasive Cardiol,2008,20(3):120-124.
[9]Balta S,Dem?rkol S,Kucuk U.The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice[J].Hemodial Int,2013,17(4):668-669.
[10]Niccoli G,Burzotta F,Galiuto L,et al.Myocardial no-reflow in humans[J].J Am Coll Cardiol,2009,54(4):281-292.
[11]Reffelmann T,Kloner RA.The no-reflow phenomenon:a basic mechanism of myocardial ischemia and reperfusion[J].Basic Res Cardiol,2006,101(5):359-372.
[12]Francone M,Bucciarelli-Ducci C,Carbone I,et al.Impact of primary coronary angioplasty delay on myocardial salvage,infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance[J].J Am Coll Cardiol,2009,54(23):2145-2153.
[13]Ito BR,Schmid-Schonbein G,Engler RL.Effects of leukocyte activation on myocardial vascular resistance［J］. Blood Cells, 1990, 16(1):145-163.
[14]Gür M,Türkoglu C,Ta?k?n A,et al.Paraoxonase-1 activity and oxidative stress in patients with anterior ST elevation myocardial infarction undergoing primary percutaneous coronary intervention with and without no-reflow[J].Atherosclerosis,2014,234(2):415-420.
[15]Eitel I,Nowak M,Stehl C,et al.Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging[J].Am Heart J,2010,159(5):882-890.
[16]Skyschally A,Schulz R,Heusch G.Pathophysiology of myocardial infarction:protection by ischemic pre- and postconditioning[J].Herz,2008,33(2):88-100.
[17]Piot C,Croisille P,Staat P,et al.Effect of cyclosporine on reperfusion injury in acute myocardial infarction[J].N Engl J Med,2008,359(5):473-481.
[18]Betgem RP,de Waard GA,Nijveldt R,et al.Intramyocardial haemorrhage after acute myocardial infarction［J］. Nat Rev Cardiol, 2015, 12(3):156-156.
[19]Iwakura K, Ito H,Kawano S,et al.Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction[J].Eur Heart J,2006,27(5):534-539.
[20]Trifunovic D,Stankovic S,Sobic-Saranovic D,et al.Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function[J].Cardiovasc Diabetol,2014,13:73.
[21]Liu N,Hou M,Ren W,et al.Clinical research of treatment with tirofiban for high-risk non-ST-segment elevation acute coronary syndrome during peri-operative intervention operation period[J].Cell Biochem Biophys,2015,71(1):43-47.
[22]Akpek M,Sahin O,Sarli B,et al.Acute Effects of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Segment Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention[J].Angiology,2015,66(6):560-567.
[23]Gu YL,Kampinga MA,Wieringa WG,et al.Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevationmyocardial infarction(CICERO)trial[J].Circulation,2010,122(25):2709- 2717.
[24]Iversen A,Abildgaard U,Galloe A,et al.Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial[J].J Interv Cardiol,2011,24(2):105-111.
[25]Ahn SG,Lee SH,Lee JH,et al.Efficacy of combination treatment with intracoronary abciximab and aspiration thrombectomy on myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing primary coronary stenting[J].Yonsei Med J,2014,55(3):606-616.
[26]Cortese B,Picchi A,Micheli A,et al.Intracoronary bivalirudin for no reflow reversal: a second chance to treat this disorder?[J].J Thromb Thrombolysis,2009,28(1):74-76.
[27]Atar D,Petzelbauer P,Schwitter J,et al.Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial[J].J Am Coll Cardiol,2009,53(8):720-729.
[28]Fokkema ML,Vlaar PJ, Vogelzang M, et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial[J].Circ Cardiovasc Interv,2009,2(4):323-329.
[29]Aung Naing K,Li L,Su Q,et al.Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction[J].Cochrane Database Syst Rev,2013,6:CD009503.
[30]Zhao S,Qi G,Tian W,et al.Effect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention: a meta-analysis[J].J Interv Cardiol,2014,27(4):356-364.
[31]Kurita A,Takashima H,Ando H,et al.Effects of eicosapentaenoic acid on peri-procedural(type IVa)myocardial infarction following elective coronary stenting[J].J Cardiol,2014,pii: S0914-5087(14)00279-2.
[32]Wu M,Huang Z,Xie H,et al.Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention:a systematic review and meta-analysis[J].PLoS One,2013,8(10):e78231.
[33]Fu Q,Lu W,Huang YJ,et al.Verapamil reverses myocardial no-reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction[J].Cell Biochem Biophys,2013,67(3):911-914.
[34]Su Q,Li L,Liu Y.Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials[J].Clin Cardiol,2013,36(8):E11-E16.
[35]Faruk Akturk I,Arif Yalcin A,Biyik I,et al.Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction[J].Minerva Cardioangiol,2014,62(5):389-397.
[36]Svilaas T,Vlaar PJ,van der Horst IC,et al.Thrombus aspiration during primary percutaneous coronary intervention[J].N Engl J Med,2008,358(6):557-567.
[37]Sardella G,Stio RE.Thrombus aspiration in acute myocardial infarction:Rationale and indication[J].World J Cardiol,2014,6(9):924-928.
[38]Kurtul A,Yarlioglues M,Murat SN,et al.Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction[J].Am J Cardiol,2014,114(3):342-347.
[39]Rivera-Linares BM,Bedolla-Barajas M,Morales-Romero J,et al.Predictors of no-reflow phenomenon after primary percutaneous coronary intervention[J].Rev Med Inst Mex Seguro Soc,2014,52(5):522-529.
[40]Rivera-Linares BM,Bedolla-Barajas M,Morales-Romero J,et al.Predictors of no-reflow phenomenon after primary percutaneous coronary intervention[J].Rev Med Inst Mex Seguro Soc,2014,52(5):522-529.
备注/Memo
- 备注/Memo:
- 收稿日期：2014-12-18.
作者简介：李少辉，硕士生 Email：2047572345@qq.com
常用功能
统计/Statistics
- 摘要浏览/Viewed725
- 评论/Comments
